Dong-Wan Kim

List of Publications by Citations

300 papers	25,385 citations	56 h-index	156 g-index
310 ext. papers	31,186 ext. citations	5.5 avg, IF	6.56 L-index

#	Paper	IF	Citations
300	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet, The*, **2016**, 387, 1540-1550	40	3964
299	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *New England Journal of Medicine*, **2013**, 368, 2385-94	59.2	2594
298	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *New England Journal of Medicine*, **2014**, 371, 2167-77	59.2	2116
297	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discovery*, **2014**, 4, 1046-61	24.4	1242
296	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2017**, 377, 829-838	59.2	1221
295	Ceritinib in ALK-rearranged non-small-cell lung cancer. *New England Journal of Medicine*, **2014**, 370, 1189-97	59.2	1119
294	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncology, The*, **2012**, 13, 1011-9	21.7	983
293	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 577-89	21.7	691
292	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *Journal of Clinical Oncology*, **2005**, 23, 2493-501	2.2	681
291	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. *Journal of Clinical Oncology*, **2016**, 34, 661-8	2.2	441
290	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2018**, 379, 2027-2039	59.2	427
289	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. *Clinical Cancer Research*, **2016**, 22, 5130-5140	12.9	397
288	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. *Journal of Clinical Oncology*, **2017**, 35, 2490-2498	2.2	366
287	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. *Journal of Clinical Oncology*, **2017**, 35, 1288-1296	2.2	363
286	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncology, The*, **2016**, 17, 452-463	21.7	318
285	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. *Journal of Clinical Oncology*, **2017**, 35, 3823-3829	2.2	298
284	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 841-849	2.2	291

283	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. *Journal of Clinical Oncology*, **2017**, 35, 3065-3074	2.2	229
282	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 2251-2258	2.2	197
281	First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 2018-2029	59.2	196
280	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. *Cancer Discovery*, **2018**, 8, 1227-1236	24.4	194
279	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. *Journal of Clinical Oncology*, **2015**, 33, 2660-6	2.2	170
278	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. *Clinical Cancer Research*, **2016**, 22, 2261-70	12.9	164
277	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1405-1411	2.2	152
276	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 3101-3109	2.2	146
275	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 1474-80	8.9	131
274	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. *Journal of Thoracic Oncology*, **2013**, 8, 415-22	8.9	126
273	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, 4079-4085	2.2	124
272	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. *Modern Pathology*, **2015**, 28, 1154-66	9.8	121
271	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). *Oncotarget*, **2016**, 7, 6984-93	3.3	115
270	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. *Journal of Clinical Oncology*, **2020**, 38, 538-547	2.2	113
269	Palliative chemotherapy for pulmonary pleomorphic carcinoma. *Lung Cancer*, **2007**, 58, 112-5	5.9	111
268	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1430-7	27.4	107
267	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. *Lung Cancer*, **2009**, 65, 80-4	5.9	105
266	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. *Journal of Clinical Oncology*, **2020**, 38, 1580-1590	2.2	104

265	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *Journal of Clinical Oncology*, **2020**, 38, 3592-3603	2.2	104
264	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. *Oncotarget*, **2016**, 7, 15901-14	3.3	101
263	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology*, **2017**, 12, 1357-1367	8.9	100
262	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 1433-1441	21.7	92
261	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. *Cancer Immunology Research*, **2016**, 4, 215-24	12.5	90
260	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 2379-87	12.9	89
259	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 767-76	3.5	88
258	Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2013**, 8, 1069-74	8.9	88
257	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1□ and STAT3. *OncoImmunology*, **2016**, 5, e1108514	7.2	88
256	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. *Journal of Clinical Oncology*, **2018**, 36, 2693-2701	2.2	87
255	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. *Journal of Thoracic Oncology*, **2019**, 14, 933-939	8.9	83
254	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2016**, 17, 263-270.e2	4.9	82
253	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. *Cancer Immunology, Immunotherapy*, **2018**, 67, 459-470	7.4	82
252	Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. *International Journal of Clinical Oncology*, **2014**, 19, 594-600	4.2	73
251	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 1132-1143	35.1	66
250	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor□esistant non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2014**, 32, 8009-8009	2.2	63
249	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. *ESMO Open*, **2017**, 2, e000219	6	62
248	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2019**, 37, 9008-9008	2.2	62

247	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *Journal of Clinical Oncology*, **2021**, 39, 3391-3402	2.2	62
246	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. *Science Translational Medicine*, **2016**, 8, 368ra172	17.5	58
245	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. *Lancet Respiratory Medicine,the*, **2017**, 5, 891-902	35.1	56
244	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1552-1560	8.9	55
243	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. *Supportive Care in Cancer*, **2006**, 14, 103-8	3.9	55
242	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. *Journal of Clinical Oncology*, **2017**, 35, 2020-2020	2.2	54
241	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. *Journal of Thoracic Oncology*, **2011**, 6, 905-12	8.9	53
240	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. *Journal of Clinical Oncology*, **2016**, 34, 9002-9002	2.2	53
239	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. *Journal of Thoracic Oncology*, **2020**, 15, 404-415	8.9	53
238	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. *Journal of Neuro-Oncology*, **2012**, 106, 303-13	4.8	52
237	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. *Lung Cancer*, **2013**, 79, 242-7	5.9	51
236	Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.. *Journal of Clinical Oncology*, **2015**, 33, 7502-7502	2.2	49
235	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. *Oncotarget*, **2017**, 8, 97920-97927	3.3	49
234	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 1794-1806	8.9	47
233	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. *Journal of Thoracic Oncology*, **2019**, 14, 1134-1155	8.9	47
232	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. *Lancet Oncology, The*, **2019**, 20, 1681-1690	21.7	47
231	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 576-584	8.9	45
230	Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**, 30, 7533-7533	2.2	45

229	Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, e147-50	2.2	43
228	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2020**, 38, 9515-9515	2.2	43
227	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. *Journal of Clinical Oncology*, **2019**, 37, 9011-9011	2.2	42
226	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. *Cancer*, **2012**, 118, 3579-86	6.4	41
225	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2020**, 38, 9512-9512	2.2	41
224	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. *Cancer Research and Treatment*, **2015**, 47, 555-63	5.2	40
223	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. *BMC Cancer*, **2019**, 19, 19	4.8	40
222	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. *Lung Cancer*, **2015**, 90, 381-7	5.9	39
221	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. *American Journal of Pathology*, **2017**, 187, 980-986	5.8	37
220	Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer. *Cancer Research and Treatment*, **2013**, 45, 325-33	5.2	34
219	Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).. *Journal of Clinical Oncology*, **2014**, 32, 8011-8011	2.2	33
218	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. *Clinical Lung Cancer*, **2019**, 20, 331-338.e4	4.9	32
217	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. *ESMO Open*, **2018**, 3, e000332	6	32
216	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 1718-1732	8.9	32
215	Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. *Blood*, **2015**, 126, 1257-8	2.2	31
214	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. *Supportive Care in Cancer*, **2013**, 21, 183-90	3.9	30
213	First-line crizotinib versus pemetrexed□isplatin or pemetrexed□arboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). *Journal of Clinical Oncology*, **2014**, 32, 8002-8002	2.2	30
212	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. *Cancer Research and Treatment*, **2018**, 50, 691-700	5.2	30

211	Scientific Advances in Thoracic Oncology 2016. *Journal of Thoracic Oncology*, **2017**, 12, 1183-1209	8.9	29
210	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. *European Journal of Cancer*, **2014**, 50, 2219-30	7.5	29
209	Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).. *Journal of Clinical Oncology*, **2018**, 36, 9009-9009	2.2	29
208	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. *Journal of Clinical Oncology*, **2019**, 37, 6018-6018	2.2	29
207	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 793-801	8.9	28
206	Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9020-9020	2.2	28
205	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. *PLoS ONE*, **2018**, 13, e0189766	2.7	28
204	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. *Lung Cancer*, **2011**, 71, 65-9	5.9	27
203	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.. *Journal of Clinical Oncology*, **2014**, 32, 8017-8017	2.2	27
202	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. *Cancer Research and Treatment*, **2019**, 51, 951-962	5.2	27
201	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. *Cancer Research and Treatment*, **2016**, 48, 907-16	5.2	27
200	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. *Lancet Respiratory Medicine,the*, **2020**, 8, 561-572	35.1	26
199	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. *Journal of Clinical Oncology*, **2016**, 34, 9044-9044	2.2	26
198	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. *Korean Journal of Internal Medicine*, **2016**, 31, 570-8	2.5	26
197	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. *Anticancer Research*, **2015**, 35, 175-82	2.3	26
196	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. *Lung Cancer*, **2017**, 106, 131-137	5.9	25
195	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. *BMC Cancer*, **2016**, 16, 116	4.8	25
194	Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. *Journal of Clinical Oncology*, **2015**, 33, 8084-8084	2.2	25

193	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. *BMC Cancer*, **2016**, 16, 170	4.8	24
192	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**, 30, 7543-7543	2.2	24
191	Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.. *Journal of Clinical Oncology*, **2013**, 31, 8010-8010	2.2	24
190	BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. *Journal of Clinical Oncology*, **2016**, 34, 9055-9055	2.2	24
189	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. *Cancer Research and Treatment*, **2017**, 49, 416-422	5.2	24
188	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1569-1579	4.9	24
187	Proportion and clinical features of never-smokers with non-small cell lung cancer. *Chinese Journal of Cancer*, **2017**, 36, 20		23
186	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. *Korean Journal of Internal Medicine*, **2016**, 31, 1140-1149	2.5	23
185	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. *Cancer Research and Treatment*, **2015**, 47, 670-5	5.2	23
184	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 1484-1496	8.9	22
183	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 736-744	3.2	22
182	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. *Journal of Thoracic Oncology*, **2015**, 10, 1189-94	8.9	22
181	First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.. *Journal of Clinical Oncology*, **2012**, 30, 7530-7530	2.2	22
180	First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.. *Journal of Clinical Oncology*, **2012**, 30, 3007-3007	2.2	21
179	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. *Journal of Clinical Oncology*, **2016**, 34, 9007-9007	2.2	21
178	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. *Oncologist*, **2019**, 24, e740-e748	5.7	21
177	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. *Oncologist*, **2019**, 24, 20-e29	5.7	21
176	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. *European Journal of Cancer*, **2017**, 82, 27-33	7.5	20

175	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. *Lung Cancer*, **2019**, 136, 122-128	5.9	19
174	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. *World Journal of Gastroenterology*, **2016**, 22, 8389-8397	5.6	19
173	Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.. *Journal of Clinical Oncology*, **2021**, 39, 9006-9006	2.2	19
172	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. *Cancer Discovery*, **2021**,	24.4	19
171	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. *Journal of Thoracic Oncology*, **2021**, 16, 2091-2108	8.9	19
170	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. *Lung Cancer*, **2019**, 135, 66-72	5.9	18
169	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. *Journal of Clinical Oncology*, **2014**, 32, 8003-8003	2.2	18
168	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. *Cancer Research and Treatment*, **2019**, 51, 119-127	5.2	18
167	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. *Clinical Infectious Diseases*, **2020**, 71, 422-425	11.6	18
166	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. *Theranostics*, **2020**, 10, 10838-10848	12.1	18
165	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. *British Journal of Cancer*, **2021**, 124, 383-390	8.7	18
164	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. *Oncologist*, **2015**, 20, 1119-20	5.7	17
163	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. *Journal of Clinical Oncology*, **2015**, 33, 8013-8013	2.2	17
162	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 3017-3017	2.2	17
161	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability-high (MSI-H) tumors.. *Journal of Clinical Oncology*, **2019**, 37, 670-670	2.2	17
160	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *Cancer Research and Treatment*, **2014**, 46, 323-30	5.2	17
159	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. *Cancer Research and Treatment*, **2015**, 47, 630-7	5.2	17
158	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial. *Thoracic Cancer*, **2020**, 11, 62-71	3.2	17

157	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. *Lung Cancer*, **2018**, 123, 14-21	5.9	16
156	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and	2.2	16
155	Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. *Journal of Clinical Oncology*, **2016**, 34, 9003-9003	2.2	16
154	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. *Journal of Thoracic Oncology*, **2019**, 14, 1556-1566	8.9	15
153	The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. *Journal of Cancer Research and Clinical Oncology*, **2014**, 140, 2135-42	4.9	15
152	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 520-528	8.9	15
151	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. *Lung Cancer*, **2014**, 86, 363-8	5.9	15
150	Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. *Journal of Thoracic Oncology*, **2014**, 9, 1523-31	8.9	15
149	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. *Journal of Clinical Oncology*, **2015**, 33, 8008-8008	2.2	15
148	AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. *Journal of Clinical Oncology*, **2015**, 33, 8016-8016	2.2	15
147	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. *Journal of Clinical Oncology*, **2017**, 35, 2006-2006	2.2	15
146	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. *Journal of Clinical Oncology*, **2018**, 36, 9061-9061	2.2	15
145	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. *Clinical Lung Cancer*, **2016**, 17, 245-252.e1	4.9	15
144	Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection. *European Radiology*, **2018**, 28, 861-868	8	15
143	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. *Lung Cancer*, **2018**, 122, 234-242	5.9	15
142	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. *Journal of Korean Medical Science*, **2014**, 29, 1094-101	4.7	14
141	Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.. *Journal of Clinical Oncology*, **2012**, 30, 7600-7600	2.2	14
140	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, 8029-8029	2.2	14

139	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9022-9022	2.2	14
138	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. *British Journal of Cancer*, **2018**, 118, 38-42	8.7	14
137	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. *Clinical Lung Cancer*, **2017**, 18, e169-e178	4.9	13
136	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 873-83	4.9	13
135	A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. *Oncologist*, **2014**, 19, 1129-30	5.7	13
134	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 324-343	8.9	13
133	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. *Cancer Biomarkers*, **2016**, 16, 425-33	3.8	13
132	Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.. *Journal of Clinical Oncology*, **2016**, 34, 9064-9064	2.2	12
131	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. *Korean Journal of Internal Medicine*, **2017**, 32, 514-522	2.5	12
130	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. *Cancer Research and Treatment*, **2016**, 48, 88-97	5.2	12
129	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2021**, 39, 9007-9007	2.2	12
128	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). *Lung Cancer*, **2016**, 93, 1-8	5.9	11
127	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. *Journal of Clinical Oncology*, **2016**, 34, 9013-9013	2.2	11
126	Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. *Journal of Clinical Oncology*, **2016**, 34, 9060-9060	2.2	11
125	Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2017**, 35, 11506-11506	2.2	11
124	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. *Journal of Clinical Oncology*, **2017**, 35, 2069-2069	2.2	11
123	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. *Journal of Clinical Oncology*, **2017**, 35, LBA9008-LBA9008	2.2	11
122	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. *Journal of Clinical Oncology*, **2018**, 36, 2513-2513	2.2	11

121	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. *Clinical Lung Cancer*, **2019**, 20, e442-e451	4.9	10
120	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. *Cancer Research and Treatment*, **2017**, 49, 1033-1043	5.2	10
119	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. *Head and Neck*, **2016**, 38, 277-84	4.2	10
118	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. *Journal of Clinical Oncology*, **2016**, 34, 9046-9046	2.2	10
117	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2017**, 35, 9036-9036	2.2	10
116	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. *Journal of Clinical Oncology*, **2017**, 35, 9090-9090	2.2	10
115	Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.. *Journal of Clinical Oncology*, **2020**, 38, 9518-9518	2.2	10
114	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. *Korean Journal of Internal Medicine*, **2019**, 34, 1313-1323	2.5	10
113	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. *Cytotherapy*, **2019**, 21, 603-611	4.8	9
112	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). *Oncotarget*, **2017**, 8, 15943-15951	3.3	9
111	AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.. *Journal of Clinical Oncology*, **2015**, 33, 8000-8000	2.2	9
110	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. *Cancer Research and Treatment*, **2018**, 50, 720-728	5.2	9
109	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. *Cancer Research and Treatment*, **2019**, 51, 1231-1240	5.2	9
108	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. *Lung Cancer*, **2020**, 139, 22-27	5.9	9
107	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. *Journal of Thoracic Oncology*, **2021**, 16, 259-268	8.9	9
106	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. *Cancer Research and Treatment*, **2016**, 48, 304-11	5.2	8
105	Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. *Supportive Care in Cancer*, **2017**, 25, 429-437	3.9	8
104	Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2015**, 33, 3047-3047	2.2	8

103	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1 positive NSCLC.. *Journal of Clinical Oncology*, **2016**, 34, 9015-9015	2.2	8
102	Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.. *Journal of Clinical Oncology*, **2016**, 34, 9066-9066	2.2	8
101	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. *Journal of Clinical Oncology*, **2017**, 35, e20504-e20504	2.2	8
100	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2018**, 36, 9094-9094	2.2	8
99	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. *Korean Journal of Internal Medicine*, **2015**, 30, 891-8	2.5	8
98	Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. *Cancer*, **2021**, 127, 1407-1416	6.4	8
97	Virtual reality-assisted localization and three-dimensional printing-enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer. *Thoracic Cancer*, **2018**, 9, 1525-1527	3.2	8
96	EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. *Japanese Journal of Clinical Oncology*, **2011**, 41, 548-54	2.8	7
95	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.. *Journal of Clinical Oncology*, **2016**, 34, 9024-9024	2.2	7
94	Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer. *International Journal of Oncology*, **2020**, 56, 559-567	4.4	7
93	A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. *Cancer Research and Treatment*, **2014**, 46, 19-26	5.2	7
92	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. *Scientific Reports*, **2021**, 11, 19712	4.9	7
91	Clinical Application of Next-Generation Sequencing-Based Panel to Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. *Molecular Cancer Therapeutics*, **2020**, 19, 937-944	6.1	7
90	A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer. *British Journal of Cancer*, **2021**, 124, 713-720	8.7	7
89	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). *Lung Cancer*, **2017**, 106, 76-82	5.9	6
88	Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. *Journal of Clinical Oncology*, **2012**, 30, 7596-7596	2.2	6
87	Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. *Journal of Clinical Oncology*, **2014**, 32, 8078-8078	2.2	6
86	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. *Journal of Clinical Oncology*, **2017**, 35, 9085-9085	2.2	6

85	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. *Journal of Clinical Oncology*, **2017**, 35, LBA9008-LBA9008	2.2	6
84	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. *Journal of Clinical Oncology*, **2018**, 36, 8575-8575	2.2	6
83	Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. *Yonsei Medical Journal*, **2016**, 57, 795-8	3	6
82	2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology. *Korean Journal of Radiology*, **2021**, 22, 263-280	6.9	6
81	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. *JTO Clinical and Research Reports*, **2021**, 2, 100205	1.4	6
80	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. *Yonsei Medical Journal*, **2018**, 59, 202-210	3	5
79	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. *Lung Cancer*, **2014**, 85, 320-3	5.9	5
78	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. *Journal of Clinical Oncology*, **2012**, 30, 3076-3076	2.2	5
77	Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. *Journal of Clinical Oncology*, **2016**, 34, e20501-e20501	2.2	5
76	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2018**, 36, 9072-9072	2.2	5
75	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. *Thoracic Cancer*, **2020**, 11, 3482-3489	3.2	5
74	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. *ESMO Open*, **2019**, 4, e000575	6	5
73	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase ()-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. *Lung Cancer: Targets and Therapy*, **2019**, 10, 125-130	2.9	5
72	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. *Thoracic Cancer*, **2019**, 10, 2117-2123	3.2	4
71	Risk stratification of symptomatic brain metastases by clinical and FDG PET parameters for selective use of prophylactic cranial irradiation in patients with extensive disease of small cell lung cancer. *Radiotherapy and Oncology*, **2020**, 143, 81-87	5.3	4
70	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. *Journal of Clinical Oncology*, **2018**, 36, 169-169	2.2	4
69	Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.. *Journal of Clinical Oncology*, **2020**, 38, 9571-9571	2.2	4
68	Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. *Cancer Research and Treatment*, **2020**, 52, 1112-1119	5.2	4

67	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. *Current Medical Research and Opinion*, **2020**, 36, 477-482	2.5	4
66	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. *Cancer Research and Treatment*, **2018**, 50, 670-680	5.2	4
65	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. *Journal of Clinical Oncology*, **2016**, 34, 3030-3030	2.2	3
64	GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ⊟ erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.. *Journal of Clinical*	2.2	3
63	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. *Journal of Clinical Oncology*, **2017**, 35, e20502-e20502	2.2	3
62	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. *Journal of Clinical Oncology*, **2019**, 37, 9026-9026	2.2	3
61	A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. *Journal of Clinical Oncology*, **2020**, 38, TPS3654-TPS3654	2.2	3
60	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. *Korean Journal of Internal Medicine*, **2019**, 34, 885-893	2.5	3
59	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. *Korean Journal of Internal Medicine*, **2019**, 34, 1116-1124	2.5	3
58	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. *Cancer Research and Treatment*, **2015**, 47, 182-8	5.2	3
57	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. *Cancer Research and Treatment*, **2017**, 49, 129-140	5.2	3
56	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. *Cancer Research and Treatment*, **2019**, 51, 169-177	5.2	3
55	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. *Journal of Clinical Oncology*, **2015**, 33, 8078-8078	2.2	3
54	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. *Cancer Letters*, **2020**, 495, 135-144	9.9	3
53	Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.. *Journal of Clinical Oncology*, **2021**, 39, 9089-9089	2.2	3
52	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ⊟ durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. *Journal of Clinical Oncology*, **2021**, 39, 9047-9047	2.2	3
51	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 619-630	3.2	3
50	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. *Journal of Clinical Oncology*, **2012**, 30, 10009-10009	2.2	2

49	A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).. *Journal of Clinical Oncology*, **2012**, 30, 7599-7599	2.2	2
48	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. *Journal of Clinical Oncology*, **2017**, 35, e20503-e20503	2.2	2
47	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. *Journal of Clinical Oncology*, **2018**, 36, 9033-9033	2.2	2
46	Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.. *Journal of Clinical Oncology*, **2020**, 38, 9572-9572	2.2	2
45	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. *Journal of Clinical Oncology*, **2020**, 38, 9574-9574	2.2	2
44	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study **2021**,		2
43	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1605-1617	7.4	2
42	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1755-1769	7.4	2
41	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. *Translational Lung Cancer Research*, **2021**, 10, 699-711	4.4	2
40	Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. *Cancer Research and Treatment*, **2021**, 53, 1195-1203	5.2	2
39	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR-Mutant NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 1859-1871	8.9	2
38	Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis. *Japanese Journal of Clinical Oncology*, **2017**, 47, 61-66	2.8	1
37	A newly developed capture-based sequencing panel for genomic assay of lung cancer. *Genes and Genomics*, **2020**, 42, 751-759	2.1	1
36	Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. *Clinical Lung Cancer*, **2014**, 15, e1-6	4.9	1
35	Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, 8108-8108	2.2	1
34	A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.. *Journal of Clinical Oncology*, **2014**, 32, TPS8124-TPS8124	2.2	1
33	Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. *Journal of Clinical Oncology*, **2017**, 35, 8547-8547	2.2	1
32	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. *Journal of Clinical Oncology*, **2019**, 37, 2558-2558	2.2	1

31	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. *Journal of Clinical Oncology*, **2020**, 38, 9601-9601	2.2	1
30	Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. *Chinese Clinical Oncology*, **2019**, 8, 27	2.3	1
29	Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. *Cancer Research and Treatment*, **2016**, 48, 458-64	5.2	1
28	Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.. *Journal of Clinical Oncology*, **2019**, 37, 9037-9037	2.2	1
27	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer. *Korean Journal of Internal Medicine*, **2021**, 36, 975-984	2.5	1
26	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. *Journal of Clinical Oncology*, **2016**, 34, e20507-e20507	2.2	1
25	Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.. *Journal of Clinical Oncology*, **2016**, 34, 9063-9063	2.2	1
24	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. *Haematologica*, **2021**, 106, 2277-2280	6.6	1
23	Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. *Journal of Clinical Oncology*, **2021**, 39, 9071-9071	2.2	1
22	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. *Scientific Reports*, **2021**, 11, 2514	4.9	1
21	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. *Lung Cancer*, **2021**, 159, 162-170	5.9	1
20	Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. *Journal of Clinical Oncology*, **2022**, 40, 434-434	2.2	0
19	Clinical Characteristics and Outcomes in Advanced -Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).. *JTO Clinical and Research Reports*, **2022**, 3, 100261	1.4	0
18	Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. *Journal of Clinical Oncology*, **2016**, 34, 9001-9001	2.2	0
17	Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.. *Journal of Clinical Oncology*, **2021**, 39, 2579-2579	2.2	0
16	Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. *Asia-Pacific Journal of Clinical Oncology*, **2021**, 17, 388-395	1.9	0
15	Detecting ALK fusions in lung cancer: multiple choice testing?. *Lung Cancer Management*, **2013**, 2, 173-175	256	
14	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. *The Korean Journal of Hematology*, **2005**, 40, 192		

13	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. *Journal of Clinical Oncology*, **2014**, 32, 9543-9543	2.2
12	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. *Journal of Clinical Oncology*, **2014**, 32, e17032-e17032	2.2
11	Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC).. *Journal of Clinical Oncology* , **2015**, 33, 6052-6052	2.2
10	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. *Journal of Clinical Oncology*, **2016**, 34, 6078-6078	2.2
9	Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.. *Journal of Clinical Oncology*, **2016**, 34, e20520-e20520	2.2
8	Korean Cancer Patients Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. *Journal of Clinical Oncology*, **2016**, 34, 10067-10067	2.2
7	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. *Journal of Clinical Oncology*, **2017**, 35, 92-92	2.2
6	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**, 30, 7566-7566	2.2
5	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. *Journal of Clinical Oncology*, **2012**, 30, 5552-5552	2.2
4	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. *Journal of Clinical Oncology*, **2013**, 31, 8521-8521	2.2
3	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. *Journal of Clinical Oncology*, **2013**, 31, 2098-2098	2.2
2	The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, 1590-1590	2.2
1	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, e18555-e18555	2.2